Patents by Inventor Maofen CHEN

Maofen CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intermediate drug with synergistic anticancer activity and polyethylene glycol-coupled synergistic anticancer drug, and preparation method therefor and use thereof
    Patent number: 11484600
    Abstract: Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: November 1, 2022
    Assignee: Chongqing Upgra Biotechnology Co., Ltd.
    Inventors: Gaoquan Li, Bin Wang, Dajun Li, Qian Zhang, Lei Huang, Maofen Chen, Xiaodan Wu, Liangyan Peng, Tingting He, Yanyan Zhang, Yun Tang, Huan Liu, Jvyuan Shui, Cuifang Zhang, Jianhuan Li
  • INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20200261588
    Abstract: Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.
    Type: Application
    Filed: January 22, 2018
    Publication date: August 20, 2020
    Applicant: Chongqing Upgra Biological Sci. & Tech., Ltd.
    Inventors: Gaoquan LI, Bin WANG, Dajun LI, Qian ZHANG, Lei HUANG, Maofen CHEN, Xiaodan WU, Liangyan PENG, Tingting HE, Yanyan ZHANG, Yun TANG, Huan LIU, Jvyuan SHUI, Cuifang ZHANG, Jianhuan LI